Incyte and Merck & Co. have decided to move a combination of their respective immunotherapies into a pivotal Phase III trial as a first-line therapy for patients with advanced metastatic melanoma. The trial, set to begin in the first half of 2016, will combine Incyte's IDO1 inhibitor epacadostat with Merck's already-approved programmed death-1 (PD-1) antagonist Keytruda (pembrolizumab).
Financial details of the collaboration were not disclosed.
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
